田基黄提取物与5-FU联合应用治疗肝细胞癌的实验性研究

目的研究田基黄提取物对H22荷瘤小鼠的抗肿瘤作用及其对化疗药物氟尿嘧啶（5-FU）的增效减毒作用。方法采用荷H22肝细胞癌小鼠为模型,在体观察田基黄醇提液和水提液单独应用以及与5-FU联合应用对荷瘤小鼠抑瘤率、脾指数和胸腺指数等的影响。结果田基黄醇提液和水提液对H22移植瘤具有一定的抑制作用,抑瘤率分别为11.49%和21.41%,两者与5-FU联合应用能提高后者对H22移植瘤的抑瘤率,但差异均无统计学意义（P〉0.05）。与对照组相比,田基黄醇提取液和水提液也能显著升高H22荷肝细胞癌小鼠的脾指数和胸腺指数。结论田基黄提取物对肝细胞癌具有一定的抑制作用,对5-FU具有一定的减毒增效作用。

Efficacy of Adefovir dipivoxil treatment in 133 patients with chronic hepatitis B

Objective To observe the efficacy of Adefovir treatment in patients with chronic hepatitis B virus infection.Methods One hundred and thirty-three chronic hepatitis B patients were selected,and divided into the no-treatment group with 101 cases and Lamivudine resistance group with 32 cases.All of the patients were given Adefovir dipivoxil for continuous 48 weeks.The automatic biochemistry analyzer,chemical luminescence instrument and real-time fluorescence gene amplification device were used.ALT,HBeAg and HBV DNA levels were detected in their serum at the first,12th week,24th week,48th week to evaluate the therapeutic effect.Results The ALT,HBeAg and HBVDNA levels of the no-treatment group dropped significantly（P0.05）.The HBV DNA level was not significantly different in the patients with various in Lamivudine-resistance mutations group.Compared with pretherapy, the levels of ALT,HBeAg and HBV DNA dropped significantly 24 weeks after Adefovir treatment（P0.05）.After 48 weeks,the levels dropped significantly than those after 24 weeks（P0.05）.Conclusion Adefovir dipivoxil can effectively reduce the levels of ALT,HBeAg and HBVDNA of the patients with chronic hepatitis B,including Lamivudine-resistance patients.